Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

Mint Med vs Belle Health

Two GLP-1 deals, scored on the same six factors. Mint Med lands a Value Score of 87, Belle Health a 85. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

Mint Med

#22 · Grade A- · Great Deal

Est. first month

$117/mo

Save ~91% vs brand-name

FDA warning letter. The FDA issued Glow Medispa, LLC dba Mint Med a warning letter in June 2026. Check it on the FDA database.

Get this deal Full Mint Med review →
VS

Belle Health

#29 · Grade A- · Great Deal

Est. first month

$119/mo

Save ~91% vs brand-name

FDA warning letter. The FDA issued Belle Health LLC dba Belle a warning letter in February 2026. Check it on the FDA database.

Get this deal Full Belle Health review →

The verdict

Better value: Mint Med

Mint Med takes it on Value Score, 87 to 85 an est. $117/mo first month, with no teaser step-up baked in. Belle Health isn't out of it: Shoppers who want flat-rate compounded GLP-1 with free weekly dietitian sessions.

Our #1 overall:Neither of these is our top pick — that's CoreAge Rx (Value Score 93).See why →

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealMint MedBelle Health
Value Score87 (A-)85 (A-)
Est. first month$117/mo$119/mo
Save vs brand-name~91%~91%
Semaglutide$117/mo$119/mo
Tirzepatide$159/moFrom $199/mo (all doses, 3-month plan, compounded)
Both moleculesYesYes
PricingFlat — no step-upFlat — no step-up
CoverageAZ, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KS, KY, ME, MD, MI, MN, MT, NV, NH, NJ, NY, NC, ND, OH, OK, PA, TN, TX, UT, VT, VA, WA, WV, WI, WYAll 50 states

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

88
Lowest Real Price
94
Mint Med: 88. Belle Health: 94.
86
No Teaser-Rate Bait
90
Mint Med: 86. Belle Health: 90.
88
Nationwide Availability
96
Mint Med: 88. Belle Health: 96.
90
Both Molecules
92
Mint Med: 90. Belle Health: 92.
84
Easy Cancellation
58
Mint Med: 84. Belle Health: 58.
82
Reputation
46
Mint Med: 82. Belle Health: 46.

Mint Med

Low flat pricing — $117 sema, $159 tirz — from a LegitScript-certified pharmacy across 36 states.

Why it's a deal

  • Low $117 semaglutide and a cheap $159 tirzepatide
  • LegitScript-certified pharmacy
  • Flat pricing on both molecules

The fine print

  • Covers 36 states, not the full 50
  • Compounded only — no brand-name or oral route

Belle Health

Belle Health is a national DTC telehealth platform offering compounded semaglutide and tirzepatide with flat-rate pricing — the same monthly cost at every dose, with no escalation surcharge as you titrate up.

Why it's a deal

  • Five named compounding pharmacy partners disclosed (Striker, Strive, OptioRx, Enovex, Braun PharmaCare)
  • Flat-rate pricing — $119/mo semaglutide, $199/mo tirzepatide — doesn't rise at higher doses
  • Free weekly registered-dietitian sessions included
  • Operating since 2017
  • LegitScript Certified

The fine print

  • $199 tirzepatide price requires a 3-month bundle commitment
  • Compounded medications are not FDA-approved
  • Multi-pharmacy model — formulations may differ across orders
  • FDA issued this company a warning letter dated 20 February 2026; the letter is public in FDA's warning-letter database
Get the Mint Med deal Get the Belle Health deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores Mint Med is ranked on the Mint Med alternatives ranking, and the same list for the other side is on alternatives to Belle Health.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.